Boceprevir dosing for late responders and null responders: The role of bridging data between treatment‐naïve and ‐experienced subjects

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 57; no. 3; pp. 903 - 907
Main Authors Florian, Jeffry, Jadhav, Pravin R., Amur, Shashi, Ayala, Ruben, Harrington, Patrick, Mishra, Poonam, O'Rear, Jules, Pacanowski, Michael, Robertson, Sarah, Singer, Mary, Soon, Greg, Zeng, Wen, Murray, Jeffrey
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.03.2013
Wolters Kluwer Health, Inc
Subjects
Antiviral Agents - administration & dosage
Antiviral Agents - therapeutic use
Clinical Trials, Phase III as Topic - methods
Drug Approval - methods
Drug Monitoring - methods
Drug Resistance, Viral
Drug Therapy, Combination - standards
Evidence-Based Medicine - methods
Hepatitis C, Chronic - drug therapy
Hepatology
Humans
Interferon-alpha - therapeutic use
Proline - administration & dosage
Proline - analogs & derivatives
Proline - therapeutic use
Ribavirin - therapeutic use
United States
United States
Online AccessGet full text

Cover

More Information
Bibliography:fax: (301)‐847‐8720
Disclaimer: the contents of the article represent the authors' personal opinion and do not necessarily reflect any position of the Food and Drug Administration.
Potential conflict of interest: Nothing to report.
Data for these analyses were submitted to the United States Food and Drug Administration by Merck as part of a new drug application.
See Editorial on Page 875
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0270-9139
1527-3350
1527-3350
DOI:10.1002/hep.25843